サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1463082

ヘビ抗毒素市場、シェア、規模、動向、産業分析レポート：タイプ別、作用機序別、エンドユーザー別、地域別、セグメント別予測、2024年～2032年

Snake Antivenom Market Share, Size, Trends, Industry Analysis Report, By Type (Polyvalent Heterologous, Monovalent Heterologous, Homologous, and Small Molecule Anti-Toxins); By Mode of Action; By End User; By Region; Segment Forecast, 2024 - 2032

出版日
ページ情報
英文 119 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.33円
ヘビ抗毒素市場、シェア、規模、動向、産業分析レポート：タイプ別、作用機序別、エンドユーザー別、地域別、セグメント別予測、2024年～2032年
出版日: 2024年03月24日
発行: Polaris Market Research
ページ情報: 英文 119 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界のヘビ抗毒素市場規模は2032年までに6億3,685万米ドルに達する見込みです。このレポートは現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

様々な地域で一般的な公衆衛生問題としてヘビ咬傷の有病率が上昇し、効果的な毒中和ソリューションや治療法に対する需要が増加しており、市場の成長を牽引しています。ヘビ咬傷の識別、管理、治療に関するヘルスケア専門家の意識が、抗毒素薬の需要を促進しています。さらに、より効果的な抗毒素製剤の開発や診断・治療法の進歩をもたらす研究開発の進展が、市場の成長をさらに押し上げると予想されます。

例えば、2023年1月、Ophirex Inc.は3,700万米ドルのシリーズB資金調達を完了したと発表しました。この資金は、広範なヘビ咬傷治療を前進させるため、臨床開発と薬事申請を継続するために使用されます。

ヘビ咬傷の負担を軽減するためには、固有種に特化した効果的で安全かつ高品質な製品を入手することが重要な要素となってきています。国家レベルでは、特に生産者の乏しい地域で使用される抗毒素については、臨床ニーズを満たすのに十分な製造量がないです。そのため、抗毒素の製造または開発能力を強化する新たな機会が生まれており、これは市場の成長にも好材料となります。

例えば、Indian Journal of Medical Researchが2023年4月に発表した報告書によると、インドは蛇咬傷の予防と制御のための国家プログラムに注力しており、新しい効果的な抗毒素の開発を奨励しています。

さらに、ヘビ抗毒素の分野における研究開発活動にも重点が置かれつつあり、これには主に、新しい改良型治療製剤の開発や全体的な治療成績の向上といった活動が含まれます。これは、患者が痛みから迅速に回復するのを助け、世界中で絶えず増加しているヘビ咬傷による死亡者数を減少させます。

ヘビ抗毒素市場レポートハイライト

多価異種製剤セグメントが最大のシェアを占める。

神経毒ヘビ咬傷の有病率の上昇とヘルスケア専門家の間での採用により、神経毒セグメントが最大シェアを占めました。

病院・診療所セグメントは、患者人口の大幅な増加と病院インフラの改善により、最も速いペースで成長します。

アジア太平洋地域は、ヘビ咬傷の発生件数が増加し、そのために死亡者数が増加しているため、世界市場を独占すると予想されます。

主な市場参入企業は、ベーリンガーインゲルハイム・サーモフィッシャー、ハミルトン社、インセプタワクチン、ノボノルディスク、希少疾患治療薬、バイオクロンなどです。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界のヘビ抗毒素市場の洞察

  • ヘビ抗毒素市場- エンドユーザースナップショット
  • ヘビ抗毒素市場力学
    • 促進要因と機会
      • ヘビに噛まれる事件の増加と研究開発活動への投資の増加
      • 政府の取り組みと資金提供
    • 抑制要因と課題
      • 抗毒素生産の高コスト
  • PESTEL分析
  • ヘビ抗毒素市場のエンドユーザー動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 タイプ別の世界市場

  • 主な調査結果
  • イントロダクション
  • 多価異種
  • 一価異種
  • 相同
  • 小分子

第6章 作用機序別の世界市場

  • 主な調査結果
  • イントロダクション
  • 細胞毒性
  • 神経毒性
  • 血液毒性
  • 心臓毒性
  • 筋毒性
  • その他

第7章 エンドユーザー別の世界市場

  • 主な調査結果
  • イントロダクション
  • 病院・クリニック
  • 外来手術センター
  • 研究機関
  • その他

第8章 地域別の世界市場

  • 主な調査結果
  • イントロダクション
    • ヘビ抗毒素市場評価、地域別、2019-2032年
  • ヘビ抗毒素市場-北米
    • 北米：ヘビ抗毒素市場、タイプ別、2019年～2032年
    • 北米：ヘビ抗毒素市場、エンドユーザー別、2019年～2032年
    • 北米：ヘビ抗毒素市場、作用機序別、2019年～2032年
    • ヘビ抗毒素市場-米国
    • ヘビ抗毒素市場- カナダ
  • ヘビ抗毒素市場- 欧州
    • 欧州：ヘビ抗毒素市場、タイプ別、2019年～2032年
    • 欧州：ヘビ抗毒素市場、エンドユーザー別2019年～2032年
    • 欧州：ヘビ抗毒素市場、作用機序別、2019年～2032年
    • ヘビ抗毒素市場- 英国
    • ヘビ抗毒素市場- フランス
    • ヘビ抗毒素市場- ドイツ
    • ヘビ抗毒素市場- イタリア
    • ヘビ抗毒素市場- スペイン
    • ヘビ抗毒素市場- オランダ
    • ヘビ抗毒素市場- ロシア
  • ヘビ抗毒素市場- アジア太平洋地域
    • アジア太平洋地域：ヘビ抗毒素市場、タイプ別、2019年～2032年
    • アジア太平洋地域：ヘビ抗毒素市場、エンドユーザー別2019年～2032年
    • アジア太平洋地域：ヘビ抗毒素市場、作用機序別、2019年～2032年
    • ヘビ抗毒素市場- 中国
    • ヘビ抗毒素市場- インド
    • ヘビ抗毒素市場- マレーシア
    • ヘビ抗毒素市場- 日本
    • ヘビ抗毒素市場- インドネシア
    • ヘビ抗毒素市場- 韓国
  • ヘビ抗毒素市場-中東およびアフリカ
    • 中東およびアフリカ：ヘビ抗毒素市場、タイプ別、2019-2032年
    • 中東およびアフリカ：ヘビ抗毒素市場、エンドユーザー別、2019-2032年
    • 中東およびアフリカ：ヘビ抗毒素市場、作用機序別、2019-2032年
    • ヘビ抗毒素市場- サウジアラビア
    • ヘビ抗毒素市場-UAE
    • ヘビ抗毒素市場- イスラエル
    • ヘビ抗毒素市場- 南アフリカ
  • ヘビ抗毒素市場-ラテンアメリカ
    • ラテンアメリカ：ヘビ抗毒素市場、タイプ別、2019年～2032年
    • ラテンアメリカ：ヘビ抗毒素市場、エンドユーザー別、2019-2032年
    • ラテンアメリカ：ヘビ抗毒素市場、作用機序別、2019年～2032年
    • ヘビ抗毒素市場- メキシコ
    • ヘビ抗毒素市場- ブラジル
    • ヘビ抗毒素市場- アルゼンチン

第9章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • パートナーシップ/コラボレーション/契約/公開

第10章 企業プロファイル

  • Bharat Serums and Vaccine Limited
  • Bioclon Institute
  • Boehringer-Ingelheim Thermo Fisher
  • Boston Scientific Corporation
  • BTG International Inc.
  • CSL Limited
  • Hamilton Company
  • Incepta Vaccine Ltd.
  • Inosan Biopharma
  • Merck & Co. Inc.
  • MicroPharm
  • Novo Nordisk A/S
  • Owen Mumford Ltd.
  • Pfizer Inc.
  • Rare Disease Therapeutics Inc.
  • VINS Bioproducts Limited
図表

List of Tables

  • Table 1 Global Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • Table 2 Global Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • Table 3 Global Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • Table 4 Snake Antivenom Market Assessment, By Geography, 2019-2032 (USD Million)
  • Table 5 North America: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • Table 6 North America: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • Table 7 North America: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • Table 8 U.S.: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • Table 9 U.S.: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • Table 10 U.S.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • Table 11 Canada: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • Table 12 Canada: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • Table 13 Canada: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • Table 14 Europe: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • Table 15 Europe: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • Table 16 Europe: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • Table 17 UK: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • Table 18 UK: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • Table 19 UK: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • Table 20 France: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • Table 21 France: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • Table 22 France: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • Table 23 Germany: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • Table 24 Germany: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • Table 25 Germany: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • Table 26 Italy: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • Table 27 Italy: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • Table 28 Italy: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • Table 29 Spain: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • Table 30 Spain: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • Table 31 Spain: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • Table 32 Netherlands: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • Table 33 Netherlands: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • Table 34 Netherlands: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • Table 35 Russia: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • Table 36 Russia: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • Table 37 Russia: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • Table 38 Asia Pacific: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • Table 39 Asia Pacific: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • Table 40 Asia Pacific: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • Table 41 China: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • Table 42 China: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • Table 43 China: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • Table 44 India: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • Table 45 India: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • Table 46 India: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • Table 47 Malaysia: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • Table 48 Malaysia: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • Table 49 Malaysia: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • Table 50 Japan: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • Table 51 Japan: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • Table 52 Japan: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • Table 53 Indonesia: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • Table 54 Indonesia: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • Table 55 Indonesia: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • Table 56 South Korea: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • Table 57 South Korea: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • Table 58 South Korea: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • Table 59 Middle East & Africa: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • Table 60 Middle East & Africa: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • Table 61 Middle East & Africa: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • Table 62 Saudi Arabia: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • Table 63 Saudi Arabia: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • Table 64 Saudi Arabia: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • Table 65 UAE: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • Table 66 UAE: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • Table 67 UAE: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • Table 68 Israel: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • Table 69 Israel: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • Table 70 Israel: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • Table 71 South Africa: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • Table 72 South Africa: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • Table 73 South Africa: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • Table 74 Latin America: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • Table 75 Latin America: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • Table 76 Latin America: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • Table 77 Mexico: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • Table 78 Mexico: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • Table 79 Mexico: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • Table 80 Brazil: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • Table 81 Brazil: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • Table 82 Brazil: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • Table 83 Argentina: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • Table 84 Argentina: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • Table 85 Argentina: Snake Antivenom Market, by End User, 2019-2032 (USD Million)

List of Figures

  • Figure 1. Global Snake Antivenom Market, 2019-2032 (USD Million)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Mode of Action
  • Figure 7. Global Snake Antivenom Market, by Mode of Action, 2022 & 2032 (USD Million)
  • Figure 8. Market by Type
  • Figure 9. Global Snake Antivenom Market, by Type, 2022 & 2032 (USD Million)
  • Figure 10. Market by End User
  • Figure 11. Global Snake Antivenom Market, by End User, 2022 & 2032 (USD Million)
  • Figure 12. Snake Antivenom Market Assessment, By Geography, 2019-2032 (USD Million)
  • Figure 13. Strategic Analysis - Snake Antivenom Market
目次
Product Code: PM4444

The global snake antivenom market size is expected to reach USD 636.85 Million by 2032, according to a new study by Polaris Market Research. The report "Snake Antivenom Market Share, Size, Trends, Industry Analysis Report, By Type (Polyvalent Heterologous, Monovalent Heterologous, Homologous, and Small Molecule Anti-Toxins); By Mode of Action; By End User; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The rising prevalence of snakebites as a common public health issue across various regions and increased demand for effective venom neutralizing solutions or treatments, driving the market's growth. Awareness among healthcare professionals about the identification, management, and treatment of snakebites, fostering the demand for antivenoms. Additionally, growing advances in R&D that results in the creation of more effective antivenom formulations and advancements in diagnostics and treatment methods, are further anticipated to boost market's growth.

For instance, in January 2023, Ophirex Inc., announced that they completed a USD 37 million Series B financing. The funds will be used to continue clinical development and regulatory submission in order to advance broad-spectrum snakebite treatment.

The access to effective, safe, and quality products that are specially tailored to the endemic species has been becoming an important component to reduce the burden of snake bites. At the national level, there is insufficient manufacturing output of antivenoms to meet the clinical needs especially for antivenoms intended for use in region with scarcity of producers. Thus, there is an emerging opportunity for manufacturing or developing antivenoms with enhanced capabilities, which will also bode well for market's growth.

For instance, according to a report published by the Indian Journal of Medical Research in April 2023, India is focusing on a national programme for prevention & control of snakebite in India that encourages the development new and effective antivenoms.

Furthermore, there is a growing emphasis on research & development activities in the field of snake antivenom which mainly includes activities like creation of new improved treatment formulations and improving the overall treatment outcomes. It helps patients quickly recover from the pain and reduces the number of constantly rising deaths due to snakebites across the globe.

Snake Antivenom Market Report Highlights

Polyvalent heterologous segment accounted for the largest share, due to its higher effectiveness and preference over alternative options

Neurotoxic segment held the maximum share, on account of rising prevalence of neurotoxic snakebites and its adoption among healthcare professionals

Hospitals & clinics segment will grow at fastest pace, owing to significant increase in patient population and improvements in hospitals infrastructure

Asia Pacific is expected to dominated the global market, due to rising incidences of snakebites and number of deaths occurs due to thus in the region

The key market players include Boehringer-Ingelheim Thermo Fisher, Hamilton Company, Incepta Vaccine, Novo Nordisk, Rare Disease Therapeutics, and Bioclon

Polaris Market Research has segmented the snake antivenom market report based on type, mode of action, end user, and region:

Snake Antivenom, Type Outlook (Revenue - USD Million, 2019 - 2032)

  • Polyvalent Heterologous
  • Monovalent Heterologous
  • Homologous
  • Small Molecule Anti-Toxins

Snake Antivenom, Mode of Action Outlook (Revenue - USD Million, 2019 - 2032)

  • Cytotoxic
  • Neurotoxic
  • Haemotoxic
  • Cardiotoxic
  • Myotoxic
  • Others

Snake Antivenom, End User Outlook (Revenue - USD Million, 2019 - 2032)

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Research Institutes
  • Others

Snake Antivenom, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Snake Antivenom Market Insights

  • 4.1. Snake Antivenom Market - End User Snapshot
  • 4.2. Snake Antivenom Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Growing incidences of snakebites and rising investments on R&D activities spurring the global market growth.
      • 4.2.1.2. Government Initiatives and Funding.
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Costs of Antivenom Production.
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Snake Antivenom Market End User Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Snake Antivenom Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • 5.3. Polyvalent Heterologous
    • 5.3.1. Global Snake Antivenom Market, by Polyvalent Heterologous, by Region, 2019-2032 (USD Million)
  • 5.4. Monovalent Heterologous
    • 5.4.1. Global Snake Antivenom Market, by Monovalent Heterologous, by Region, 2019-2032 (USD Million)
  • 5.5. Homologous
    • 5.5.1. Global Snake Antivenom Market, by Homologous, by Region, 2019-2032 (USD Million)
  • 5.6. Small Molecule
    • 5.6.1. Global Snake Antivenom Market, by Small Molecule, by Region, 2019-2032 (USD Million)

6. Global Snake Antivenom Market, by Mode of Action

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • 6.3. Cytotoxic
    • 6.3.1. Global Snake Antivenom Market, by Cytotoxic, by Region, 2019-2032 (USD Million)
  • 6.4. Neurotoxic
    • 6.4.1. Global Snake Antivenom Market, by Neurotoxic, by Region, 2019-2032 (USD Million)
  • 6.5. Haemotoxic
    • 6.5.1. Global Snake Antivenom Market, by Haemotoxic, by Region, 2019-2032 (USD Million)
  • 6.6. Cardiotoxic
    • 6.6.1. Global Snake Antivenom Market, by Cardiotoxic, by Region, 2019-2032 (USD Million)
  • 6.7. Myotoxic
    • 6.7.1. Global Snake Antivenom Market, by Myotoxic, by Region, 2019-2032 (USD Million)
  • 6.8. Others
    • 6.8.1. Global Snake Antivenom Market, by Others, by Region, 2019-2032 (USD Million)

7. Global Snake Antivenom Market, by End User

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • 7.3. Hospitals & Clinics
    • 7.3.1. Global Snake Antivenom Market, by Hospitals & Clinics, By Region, 2019-2032 (USD Million)
  • 7.4. Ambulatory Surgical Centers
    • 7.4.1. Global Snake Antivenom Market, by Ambulatory Surgical Centers, By Region, 2019-2032 (USD Million)
  • 7.5. Research Institutes
    • 7.5.1. Global Snake Antivenom Market, by Research Institutes, By Region, 2019-2032 (USD Million)
  • 7.6. Others
    • 7.6.1. Global Snake Antivenom Market, by Others, By Region, 2019-2032 (USD Million)

8. Global Snake Antivenom Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Snake Antivenom Market Assessment, By Geography, 2019-2032 (USD Million)
  • 8.3. Snake Antivenom Market - North America
    • 8.3.1. North America: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
    • 8.3.2. North America: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
    • 8.3.3. North America: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
    • 8.3.4. Snake Antivenom Market - U.S.
      • 8.3.4.1. U.S.: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
      • 8.3.4.2. U.S.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
      • 8.3.4.3. U.S.: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
    • 8.3.5. Snake Antivenom Market - Canada
      • 8.3.5.1. Canada: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
      • 8.3.5.2. Canada.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
      • 8.3.5.3. Canada: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • 8.4. Snake Antivenom Market - Europe
    • 8.4.1. Europe: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
    • 8.4.2. Europe.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
    • 8.4.3. Europe: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
    • 8.4.4. Snake Antivenom Market - UK
      • 8.4.4.1. UK: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
      • 8.4.4.2. UK.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
      • 8.4.4.3. UK: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
    • 8.4.5. Snake Antivenom Market - France
      • 8.4.5.1. France: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
      • 8.4.5.2. France.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
      • 8.4.5.3. France: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
    • 8.4.6. Snake Antivenom Market - Germany
      • 8.4.6.1. Germany: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
      • 8.4.6.2. Germany.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
      • 8.4.6.3. Germany: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
    • 8.4.7. Snake Antivenom Market - Italy
      • 8.4.7.1. Italy: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
      • 8.4.7.2. Italy.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
      • 8.4.7.3. Italy: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
    • 8.4.8. Snake Antivenom Market - Spain
      • 8.4.8.1. Spain: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
      • 8.4.8.2. Spain.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
      • 8.4.8.3. Spain: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
    • 8.4.9. Snake Antivenom Market - Netherlands
      • 8.4.9.1. Netherlands: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
      • 8.4.9.2. Netherlands.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
      • 8.4.9.3. Netherlands: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
    • 8.4.10. Snake Antivenom Market - Russia
      • 8.4.10.1. Russia: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
      • 8.4.10.2. Russia.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
      • 8.4.10.3. Russia: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • 8.5. Snake Antivenom Market - Asia Pacific
    • 8.5.1. Asia Pacific: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
    • 8.5.2. Asia Pacific.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
    • 8.5.3. Asia Pacific: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
    • 8.5.4. Snake Antivenom Market - China
      • 8.5.4.1. China: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
      • 8.5.4.2. China.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
      • 8.5.4.3. China: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
    • 8.5.5. Snake Antivenom Market - India
      • 8.5.5.1. India: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
      • 8.5.5.2. India.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
      • 8.5.5.3. India: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
    • 8.5.6. Snake Antivenom Market - Malaysia
      • 8.5.6.1. Malaysia: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
      • 8.5.6.2. Malaysia.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
      • 8.5.6.3. Malaysia: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
    • 8.5.7. Snake Antivenom Market - Japan
      • 8.5.7.1. Japan: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
      • 8.5.7.2. Japan.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
      • 8.5.7.3. Japan: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
    • 8.5.8. Snake Antivenom Market - Indonesia
      • 8.5.8.1. Indonesia: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
      • 8.5.8.2. Indonesia.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
      • 8.5.8.3. Indonesia: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
    • 8.5.9. Snake Antivenom Market - South Korea
      • 8.5.9.1. South Korea: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
      • 8.5.9.2. South Korea.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
      • 8.5.9.3. South Korea: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • 8.6. Snake Antivenom Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
    • 8.6.2. Middle East & Africa.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
    • 8.6.3. Middle East & Africa: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
    • 8.6.4. Snake Antivenom Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
      • 8.6.4.2. Saudi Arabia.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
      • 8.6.4.3. Saudi Arabia: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
    • 8.6.5. Snake Antivenom Market - UAE
      • 8.6.5.1. UAE: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
      • 8.6.5.2. UAE.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
      • 8.6.5.3. UAE: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
    • 8.6.6. Snake Antivenom Market - Israel
      • 8.6.6.1. Israel: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
      • 8.6.6.2. Israel.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
      • 8.6.6.3. Israel: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
    • 8.6.7. Snake Antivenom Market - South Africa
      • 8.6.7.1. South Africa: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
      • 8.6.7.2. South Africa.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
      • 8.6.7.3. South Africa: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • 8.7. Snake Antivenom Market - Latin America
    • 8.7.1. Latin America: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
    • 8.7.2. Latin America.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
    • 8.7.3. Latin America: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
    • 8.7.4. Snake Antivenom Market - Mexico
      • 8.7.4.1. Mexico: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
      • 8.7.4.2. Mexico.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
      • 8.7.4.3. Mexico: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
    • 8.7.5. Snake Antivenom Market - Brazil
      • 8.7.5.1. Brazil: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
      • 8.7.5.2. Brazil.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
      • 8.7.5.3. Brazil: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
    • 8.7.6. Snake Antivenom Market - Argentina
      • 8.7.6.1. Argentina: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
      • 8.7.6.2. Argentina.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
      • 8.7.6.3. Argentina: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Bharat Serums and Vaccine Limited
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Bioclon Institute
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Boehringer-Ingelheim Thermo Fisher
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Boston Scientific Corporation
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. BTG International Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. CSL Limited
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Hamilton Company
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Incepta Vaccine Ltd.
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Inosan Biopharma
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Merck & Co. Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. MicroPharm
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Novo Nordisk A/S
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Owen Mumford Ltd.
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Benchmarking
    • 10.13.4. Recent Development
  • 10.14. Pfizer Inc.
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Benchmarking
    • 10.14.4. Recent Development
  • 10.15. Rare Disease Therapeutics Inc.
    • 10.15.1. Company Overview
    • 10.15.2. Financial Performance
    • 10.15.3. Product Benchmarking
    • 10.15.4. Recent Development
  • 10.16. VINS Bioproducts Limited
    • 10.16.1. Company Overview
    • 10.16.2. Financial Performance
    • 10.16.3. Product Benchmarking
    • 10.16.4. Recent Development